Article Text

Download PDFPDF
The IGF axis and hepatocarcinogenesis
  1. J-G Scharf1,
  2. F Dombrowski2,
  3. G Ramadori1
  1. 1Department of Medicine, Division of Gastroenterology and Endocrinology, Georg- August-Universität, D-37075 Göttingen, Germany
  2. 2Institute of Pathology, Rheinische Friedrich- Wilhelms-Universität, D-53127 Bonn, Germany
  1. Dr Scharf, Department of Medicine, Division of Gastroenterology and Endocrinology, Robert-Koch-Str. 40, D-37075 Göttingen, Germany jscharf{at}med.uni-goettingen.de

Abstract

Deregulation of the insulin-like growth factor (IGF) axis, including the autocrine production of IGFs, IGF binding proteins (IGFBPs), IGFBP proteases, and the expression of the IGF receptors, has been identified in the development of hepatocellular carcinoma (HCC). Characteristic alterations detected in HCC and hepatoma cell lines comprise the increased expression of IGF-II and the IGF-I receptor (IGF-IR), which have emerged as crucial events in malignant transformation and the growth of tumours. Alterations of IGFBP production and the proteolytic degradation of IGFBPs resulting in an excess of bioactive IGFs, as well as the defective function of the IGF degrading IGF-II/mannose 6-phosphate receptor (IGF-II/M6PR), may further potentiate the mitogenic effects of IGFs in the development of HCC.

  • insulin-like growth factors
  • insulin-like growth factor binding proteins
  • insulin-like growth factor I receptor
  • insulin-like growth factor II/mannose 6-phosphate receptor
  • hepatocarcinogenesis
  • hepatocellular carcinoma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes